Approved Drugs Might Work in More Cancers.
Researchers in the Netherlands presented preliminary results from a multiarm precision medicine trial at the recent ESMO 2017 Congress in Madrid, Spain. The trial, which matches patients with approved drugs based on mutations in their tumor and tissue type, has the potential to uncover treatment options for patients who have exhausted standard therapies, as well as those with rare cancers.